Clinical Trial Update: Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme [Phase 2]

View source ↗

Summary

Phase II trial of erlotinib plus sirolimus in recurrent malignant glioma (glioblastoma and gliosarcoma) has completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Duke University | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2013-04-04